New catalytic technologies impactful to synthesis of pharmaceuticals - . Modern pharmaceutical synthesis faces significant challenges in the production of complex, fluorinated, and highly functional…

Active Project Grant Awarded Last action

Award ID
R35GM159617
Recipient
Awarding agency
Obligated
$801,487

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date 23% complete
Place of performance
Columbia, MO 65211, USA

Award details come from USAspending.gov.

Description

New catalytic technologies impactful to synthesis of pharmaceuticals - . Modern pharmaceutical synthesis faces significant challenges in the production of complex, fluorinated, and highly functional molecules that are essential for ensuring the safety, potency, and stability of life-saving medications. This research program aims to address these challenges by developing safer and more efficient chemical methods that develop and leverage water-based reactions, cost-effective reagents, recyclable materials, and resource-efficient catalysts. The handa lab is set to lead innovations such as electromicellar catalysis in water, resource-efficient fluorination and trifluoromethylation of (hetero)aromatics, c-n cross-couplings of difficult molecules, and selective catalysis involving transient PD(III) species, thereby enabling the synthesis of functionally enriched compounds, nitrogen-rich atropisomers, and other intricate drug components under mild conditions. Key research areas encompass: (1) electromicellar catalysis for the formation of fluorinated heterocycles, allenes, and reactive intermediates to access trifluoromethylated (hetero)aromatics using in situ derived reagents from safer sources; (2) enantioselective cross-couplings to access challenging atropisomers through the use of recyclable catalysts and in-house developed photoactive polymers that facilitate dexter energy transfer; and (3) room-temperature cross-couplings of unreactive (hetero)aryl fluorides and chlorides, driven by surface-faceting or transient hot catalytic species, along with in situ regeneration of inactive catalysts to highly active forms. These strategies aim to enhance reaction selectivity, reduce costs, and improve safety, thereby making pharmaceutical manufacturing more efficient and accessible. Additionally, the program emphasizes the importance of training students in cutting-edge chemistry relevant to pharmaceuticals and fostering strong partnerships with the domestic pharmaceutical industry to translate discoveries into real-world health solutions.

Transactions

Action Obligated Date
Amendment $414,870
Original award $386,617

Quick answers

Who received award R35GM159617?

R35GM159617 was awarded to University Of Missouri System by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2025.

How much is award R35GM159617 worth?

$801,487 has been obligated on R35GM159617.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award